Search Videos and More
News
Faculty Updates
Faculty Updates
Podcast
Season 1, Episode 5: Turning Science Fiction into Fact
It's always fun to think about the future. Flying cars. Cities in the clouds. Colonies on Venus and Mars. OK, we didn't end up living like the Jetsons.
News
Genetic Signature of Tumor Cells Predicts Response to Chemotherapy Drug for Patients with Form of Ovarian Cancer
For more than two decades, the chemotherapy drug gemcitabine has been a mainstay treatment for several types of cancer, producing remissions in many patients on its own or conjunction with other drugs. Now, scientists at Dana-Farber Cancer Institute have uncovered, for the first time, genetic evidence of which patients with high-grade serous ovarian cancer (HGSOC) are likely to benefit from the drug.
News
Highlights in Lung Cancer From ESMO 2021 - Pasi Jänne, MD, PhD, Discusses Promising Studies from the Meeting
In this exclusive MedPage Today video, ESMO Scientific Co-Chair Pasi A. Jänne, MD, PhD, director of the Chen-Huang Center for EGFR-Mutant Lung Cancer at Dana-Farber Cancer Institute in Boston, highlights some of the important lung cancer abstracts from the conference.
News
New Study Shows Young Women With Breast Cancer Who Opt for Mastectomies Report Lower Quality of Life
Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, as detailed in new research by Dana-Farber Brigham Cancer Center.
News
Newsweek Names Dana-Farber #3 in the World for Cancer
Dana-Farber Cancer Institute has been named one of the world’s very best cancer hospitals by Newsweek in its new World’s Best Specialized Hospitals 2022 rankings.
News
Benefit of Immunotherapy Combination for Patients with Advanced Melanoma Extends to Subsequent Treatment, Study Finds
A combination of two immunotherapy drugs, already shown to be more effective in patients with advanced melanoma than one of the drugs alone, also prolongs the benefit to patients who receive subsequent therapies, a clinical trial led by Dana-Farber Cancer Institute investigators indicates. The findings will be presented today at the 2021 Congress of the European Society of Medical Oncology (ESMO).
News
Antibody-Drug Conjugate Shows Impressive Activity in Patients with Non-Small Cell Lung Cancer with Mutation in HER2 Gene
More than half of patients with non-small cell lung cancer (NSCLC) bearing a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug that hitches a chemotherapy agent to a highly targeted antibody, an international clinical trial led by investigators at Dana-Farber Cancer Institute has found.
News
Researchers Set Sights on New Ovarian Cancer Treatment Strategies
Despite breakthrough treatments for high-grade serous ovarian cancer, about 80 percent of patients relapse within two years, often resistant to treatment. The good news is that Dana-Farber scientists are pursuing multiple avenues of research that very well may improve outcomes.
News
Five Dana-Farber Cancer Institute Faculty Members are Inducted in the 2021 Giants of Cancer Care®
Five Dana-Farber Cancer Institute faculty members are inductees of the 2021 Giants of Cancer Care® program.
News
New Research Initiative Launches for All Patients Ever Diagnosed with Colorectal Cancer
Count Me In, a nonprofit cancer research initiative, is inviting all patients across the United States and Canada who have ever been diagnosed with colorectal cancer to participate in research and help drive new discoveries related to this disease.
News
Dosing Strategies Help Personalize Care in HER2+ Breast Cancer
Sara M. Tolaney, MD, MPH, discusses progress made with escalation and de-escalation strategies in HER2-positive breast cancer, ongoing research with immunotherapy, and efforts being made to further move the needle forward.